Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The FDA is investigating the risk of new lymphoma among patients receiving the engineered T cells, but so far, cases are rare.
As the population ages, more family caregivers are being pressed into service.
Two women share tips on caring for a spouse going through blood cancer treatment.
Novel treatment relies on a newer form of CRISPR gene-editing technology called base editing.
The Leukemia & Lymphoma Society’s Dare to Dream project helps pediatric cancer patients like Cayden, who received CAR-T therapy.
“I envision LLS continuing to be a leading innovator, driving change that impacts all cancer care,” says E. Anders Kolb, MD.
For the research team, the question was: “Can we turn something that is good for the cancer into something that will kill [it]?”
House Majority Leader Scalise will continue to work while undergoing treatment for multiple myeloma.
That’s a new blood cancer diagnosis approximately every three minutes.
The Leukemia & Lymphoma Society funded research leading to a type of targeted immunotherapy called bispecific antibodies.
The FDA approved Vanflyta (quizartinib) with chemotherapy for FLT3-mutated AML, an aggressive type of blood cancer.
The experimental drug motixafortide helps blood-forming stem cells move from a person’s bone marrow into the bloodstream.
Loui J. DeGennaro, PhD, served 18 years at LLS, a nonprofit funder of blood cancer research and clinical trials.
Dan Sherbenou, MD, PhD, received an American Cancer Society grant to study resistance to three key treatments for a blood cancer.
Vallurupalli, of Dana-Farber Cancer Institute, researches blood cancers and is passionate about equitable access to precision cancer care.
New research from Dana-Farber Cancer Institute has identified 116 genes as key molecular vulnerabilities for multiple myeloma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.